Drugs / 18F-PSMA-1007
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials | ||||||
| Phase 2 | NCT05712174 | Sep 2023 → May 2025 | prostate cancer | AHS Cancer Control Alberta | Terminated | No outcome recorded |
| Phase 2 | NCT05815316 | Apr 2023 → Jul 2025 | prostate cancer | IRCCS San Raffaele | Withdrawn | No outcome recorded |
| Phase 2 | NCT04053842 | Feb 2021 → Jan 2024 overdue | prostate adenocarcinoma | Glenn Bauman | Active not recruiting | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT06122584 | Jun 2024 → Mar 2027 expected | prostate cancer | ABX advanced biochemical compounds GmbH | Recruiting | No outcome recorded |
| Phase 3 | NCT04742361 | Aug 2021 → Jun 2023 | prostate cancer | ABX advanced biochemical compounds GmbH | Completed | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT05534594 | Aug 2022 → Dec 2024 | medullary thyroid gland carcinoma | University Medical Center Groningen | Completed | No outcome recorded |
| — | NCT05448404 | Mar 2022 → May 2023 | plasma cell myeloma | First Hospital of China Medical University | Unknown | No outcome recorded |
| — | NCT03187990 | Mar 2017 → Aug 2021 | prostate cancer | Irene Burger | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06881823 Comparator | Jun 2026 → Mar 2030 | prostate cancer | Novartis Pharmaceuticals | Withdrawn | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 18F-PSMA-1007 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06881823 ↗ |
| Known as | Fluorine-18 labeled prostate specific membrane antigen | “Patients with Medullary Thyroid Cancer undergo a PET/CT after receiving the Fluorine-18 labeled prostate specific membrane antigen (18F-PSMA-1007) tracer intravenously.” NCT05534594 ↗ |
| Modality | Diagnostic / imaging agent | “[18F]PSMA-1007 PET/CT for biopsy guidance and intraoperative target verification.” NCT03187990 ↗ |
| Route | Intravenous | “[18F]PSMA-1007 is given by intravenous (IV) injection into the arm.” NCT04053842 ↗ |